PDVAC Agenda 2020: An update from the Vaccine Innovation Prioritisation Strategy (VIPS)

Overview

2020 WHO Product Development for Vaccines Advisory Committee (PDVAC) Virtual Consultation 5: An update from the Vaccine Innovation Prioritisation Strategy (VIPS): 8 July 2020

CHAIR: David Kaslow

By prioritising innovations in vaccine products, the goal of VIPS is to provide greater clarity to manufacturers and partners to inform and influence investment decisions. VIPS outcomes also represent a catalyst to mobilise key decision-makers and funders and to chart a strategic pathway forward for the prioritised innovations. 

The next steps for the VIPS Alliance are to define end-to-end strategies for the 3 prioritised innovations, including developing clear action plans to accelerate their advancement to uptake and impact.

Objectives of the meeting:

• To inform vaccine development stakeholders about the VIPS process and prioritisation outcomes;
• To discuss if and how these outcomes could be incorporated into product development strategies for pipeline vaccines;
• To identify ways to promote awareness of desirable product presentation attributes and their impact on programmatic delivery considerations for pipeline vaccines